SearchIP Handbook Blog
Your source for expert commentary on IP management issues. About |
Home > Author Index > BROWN, Alfred (Buz) BROWN, Alfred (Buz)
Contributions
|
Get the printed IP Handbook or its Executive Guide.
|
Printer Friendly.jpg)
Alfred Brown has served as the President of BCM Technologies (BCMT) since 2003. He is its chief visionary and was responsible for transforming BCM Technologies into BCM Ventures. He has over 30 years of experience in biotechnology commercialization and venture creation, including large pharmaceutical, biotech, academic and venture capital roles, with particular expertise in the areas of cancer, immunology, regenerative medicine, molecular diagnostics, and predictive medicine. Before joining BCMT, Dr. Brown was Director of the Office of Cooperative Research at the Yale School of Medicine, where he co-developed the “Yale Model” of academic venture creation with Drs. Gardiner, Soderstrom, and Swartley. The Yale Model is now recognized as one of the leading academic technology commercialization and venture creation programs. Dr. Brown has helped to create many companies, including Achillion Pharmaceuticals (in registration), Applied Spine Technologies, HistoRx, Kemia, RibX Pharmaceuticals, and VaxInnate. Before working at Yale, Dr. Brown served as founder and CEO of Penn Technology Group, Knowledge Express Data System and Ontyx, Inc. (now Apelon, Inc.). He started his professional career at SmithKline & French Labs in immunology and cancer drug research and later assumed responsibility for strategic planning and biotechnology business development. Dr. Brown has a B.A. in biology from Colby College, a Ph.D. in pharmacology and toxicology from the University of Rochester School of Medicine; in addition, he has completed a post-doctoral fellowship in the Pharmacology Department at the Yale School of Medicine. He serves on the boards of Oncovance Technologies, Molecular LogiX, Kardia Therapeutics, Progression Therapeutics, and EnVivo Pharmaceuticals (observer). Dr. Brown will serve as the managing director of BCMV and focus his efforts on investments in the areas of therapeutics, diagnostics, and devices.
Show All Abstracts
Abstract